Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Phase 1/2 Completed 47 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Swim Across America · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will be looking at whether gemcitabine, taxotere, and xeloda (GTX) in combination with cisplatin and irinotecan is effective (anti-tumor activity) and safe in patients with metastatic pancreatic cancer.

Timeline

Start: 2015-02
Primary completion: 2019-06
Completion: 2020-02

Publications

Christenson ES, Lim SJ, Durham J, De Jesus-Acosta A, Bever K, Laheru D, Ryan A, Agarwal P, Scharpf RB, Le DT, Wang H. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Res Commun. 2022 Nov 11;2(11):1418-1425. doi: 10.1158/2767-9764.CRC-22-0343. eCollection 2022 Nov.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	500 mg	Oral
Subject	Cisplatin	Other / unclassified	15 mg/m2	Intravenous
Subject	Cisplatin	Other / unclassified	20 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	20 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	400 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	500 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	20 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	40 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	60 mg/m2	Intravenous

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Summary

Timeline

Publications

Drugs

Indications